Precautions for Selpercatinib
When using Selpercatinib, special attention should be paid to adverse reactions such as liver toxicity, interstitial lung disease, and hypertension, and the dosage should be adjusted or discontinued according to the degree of toxicity. People of childbearing age should strictly use contraception, and should not take supplements if missed. Regular monitoring of liver function, blood pressure, and other indicators is necessary.
1. Main Adverse Reaction Management
(1) Hepatotoxicity: When ALT/AST levels exceed 5 times the normal upper limit or bilirubin levels increase, treatment should be interrupted. After recovery, the dosage can be reduced and continued to be used.
(2) Interstitial lung disease: Any grade related symptoms should be immediately and permanently discontinued, and the condition of the lungs should be evaluated.
(3) Hypertension: Regularly monitor blood pressure before and during treatment. Medication should be suspended and blood pressure controlled if the condition is grade 3 or above.
2. Special medication precautions
(1) Omission treatment: If it is less than 12 hours before the next administration, it should be skipped, and supplementation or doubling of dosage is prohibited.
(2) Vomiting treatment: Vomiting after taking medication does not require supplementation, and the next dose should be taken strictly according to the original plan.
(3) Before and after surgery: Discontinue medication for at least 5 days before elective surgery, and discontinue medication for at least 2 weeks after major surgery and before wound healing.
3. Key monitoring requirements
(1) Liver function: ALT/AST testing every 2 weeks before treatment and for the first 3 months, followed by monthly follow-up.
(2) Electrocardiogram: Discontinue treatment when QT interval>500ms, reduce dosage after improvement.
(3) Blood sugar: If sustained hyperglycemia (>250mg/dL) occurs, pause and adjust the glycemic control plan.
4. Warning for special groups of people
(1) Pregnant women: with embryotoxicity, effective contraception is required during treatment and one week after discontinuation of medication.
(2) Breastfeeding period: Breastfeeding is prohibited from the medication period until one week after the last administration.
(3) Children: The safety of patients under 12 years old has not been established and is not recommended for use.
Disclaimer：《Precautions for Selpercatinib》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！